Théa's news

Climate Roadmap Théa

Théa announces roadmap aligned with global climate neutrality objectives

Théa, announces the development of a structured roadmap to reduce its greenhouse gas emissions, in alignment with international climate objectives and the global ambition of carbon neutrality by 2045.

2/18/26

First Patient In (FPI) Achieved in Phase 2 Trial of TLM-003 for Myopia Progression Innovation

First Patient In (FPI) Achieved in Phase 2 Trial of TLM-003 for Myopia Progression

Tsubota Laboratory announces the achievement of First Patient In (FPI) in the global Phase 2 clinical trial of TLM-003, an investigational eye drop developed to suppress myopia progression, marking a key milestone in its international clinical dev...

2/11/26

Iolyx Therapeutics Enters Strategic Agreement with Théa Théa

Iolyx Therapeutics Enters Strategic Agreement with Théa

Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline.

12/4/25

Thea x Sepulbio Théa

Sepul Bio, an innovative business unit of Théa, Doses First Participant in Phase 3 HYPERIONclinical trial of sepofarsen for CEP290-associated Leber Congenital Amaurosis Type 10

Sepul Bio: Théa’s Innovative Unit Doses First in Phase 3 HYPERION Trial for LCA10

10/1/25

Théa Opens a New Chapter in Retinal Diseases Pathology / Innovation

Théa Opens a New Chapter in Retinal Diseases

Théa Opens a New Chapter in Retinal Diseases

9/29/25

Nordics International

Official opening of the Stockholm office!

A new chapter for the Nordic region

8/28/25

Théa x Lenz Therapeutics Corporate

Licensing agreement between LENZ Therapeutics and Laboratoires Théa

New partnership Théa and Lenz Therapeutics

8/27/25

This year, ABAK® celebrating 30 years of innovation. Théa

This year, ABAK® celebrates its 30th anniversary!

This year, ABAK® celebrating 30 years of innovation.

8/27/25